FindTrial
Sign In

Development of NTAA criteria to predict OS in HCC patients with BCLC B and Child-Pugh A undergoing TACE: a retrospective study of multicenter validation

Development of NTAA criteria to predict OS in HCC patients with BCLC B and Child-Pugh A undergoing TACE: a retrospective study of multicenter validation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500099402
Enrollment
Unknown
Registered
2025-03-24
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Primary study cohort:Transarterial chemoembolization
Internal validation cohort:Transarterial chemoembolization
Multicenter external validation cohort:Transarterial chemoembolization

Sponsors

Sun Yat-sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Age over 18; 2) Diagnosis of HCC by imaging or pathology; 3) BCLC stage B; 4) Child-Pugh class A liver function; 5) HBV infection only; 6) Eastern Cooperative Oncology Group (ECOG) score of 0; 7) No radiological evidence of extrahepatic metastases or vascular invasion.

Exclusion criteria

Exclusion criteria: 1) Severe coagulopathy; 2) Child-Pugh class B, C, or ALBI score of 3; 3) Presence of extrahepatic metastases or vascular invasion; 4) ECOG score>=1; 5) Having two or more types of malignant tumors; 6) Incomplete essential baseline data.

Design outcomes

Primary

MeasureTime frame
Overall survival;—

Secondary

MeasureTime frame
Progression-free survival;—

Countries

China

Contacts

Public ContactWeijun Fan

Sun Yat-sen University Cancer Center

strugglingchen@126.com+86 138 2615 4530

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026